title: Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
abstract: OBJECTIVE
  Investigating relationship between bone markers, cytokines and conventional prognostic parameters in patients with multiple myeloma (MM) and to assess the clinical application of bone turnover markers.
  
  
  METHODS
  Sixty-four patients with MM were examined before treatment and followed for survival for over 7 years. Serum concentrations of bone markers and cytokines were determined by the Roche and R&D kits, respectively. Standard deviation scores (SDS) were employed to normalize values.
  
  
  RESULTS
  Collagen fragments (beta-CTX) were elevated in 47%, procollagen I amino-terminal propeptide (PINP)-in 28%, and osteocalcin (OC) in 11% of patients. The values of the SDS of PINP and OC, but not beta-CTX significantly decreased with MM stage. beta-CTX inversely correlated with vascular endothelial growth factor (VEGF) and albumin, and directly correlated with serum macrophage colony-stimulating factor (M-CSF). OC values correlated with albumin and beta2-microglobulin. PINP inversely correlated with LDH. The SDS values of PINP were significantly lower in MM patients with advanced bone disease.
  
  
  CONCLUSIONS
  Circulating PINP concentration may be a useful marker for monitoring of treatment of multiple myeloma patients with bone lytic lesions, in particular, of patients treated with preoteasome inhibitors.
authors.affiliation: Department of Tumor Markers, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre ul. W.K. Roentgena 5, 02-781 Warszawa, Poland. mkowalska@coi.pl
authors.forename: Maria
authors.initials: M
authors.lastname: Kowalska
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Druzd-Sitek
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Fuksiewicz
authors.forename: Beata
authors.initials: B
authors.lastname: Kotowicz
authors.forename: Magdalena
authors.initials: M
authors.lastname: Chechlinska
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Syczewska
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.forename: Janina
authors.initials: J
authors.lastname: Kaminska
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001862:Bone Resorption / Q000097:blood / Q000209:etiology; D024042:Collagen Type I / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D015675:Osteocalcin / Q000097:blood; D010446:Peptide Fragments / Q000097:blood* / Q000502:physiology; D010455:Peptides / Q000097:blood; D011347:Procollagen / Q000097:blood* / Q000502:physiology; D011379:Prognosis; D012680:Sensitivity and Specificity; D012737:Sex Factors; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D024042:Collagen Type I; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C047202:procollagen Type I N-terminal peptide; D015675:Osteocalcin